Addictovigilance contribution during COVID-19 epidemic and lockdown in FranceMaryse Lapeyre‐Mestre, Juliana Tournebize|Therapies|2020Cited by 72
Early Detection of Prescription Drug Abuse Using Doctor Shopping Monitoring From Claims Databases: Illustration From the Experience of the French Addictovigilance NetworkThomas Soeiro, Joëlle Micallef, Clémence Lacroix et al.|Frontiers in Psychiatry|2021Cited by 20
Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance NetworkPauline Gandolfo, Joëlle Micallef, Valérie Gibaja et al.|Fundamental and Clinical Pharmacology|2024Cited by 13
Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022Clément Garnier, Joëlle Micallef, Clémence Lacroix et al.|CNS Drugs|2024Cited by 8
French national addictovigilance follow-up of zolpidem between 2014 and 2020: evolution of drug abuse, misuse and dependence before and after the regulatory changeAurélie Aquizerate, Caroline Victorri‐Vigneau, Edouard‐Jules Laforgue et al.|European Journal of Public Health|2023Cited by 6